-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Climb Bio, Raises Price Target to $25

Benzinga·09/03/2026 18:01:54
Listen to the news
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.